On March 23, 2022 Centenaire Biosciences reported the company had attracted a total of 20 billion won in Series A investment from SD Biosensor’s affiliates Bionote and SDB Investment on the 18th (Press release, Centenaire Biosciences, MAR 23, 2022, View Source [SID1234643838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sanctnaire, which is developing an innovative antibody platform centered on the field of anti-cancer and immune disease treatment, has succeeded in attracting large-scale investment within 10 months of its establishment, and is developing, pipeline expansion, and additional platforms for clinical entry of its core pipeline ‘CTN001’. We plan to use the investment for technology development.

Centenaire, which has the goal of ‘development of innovative new drugs for the era of average lifespan of 100 years’ with the French word ‘Centenaire’ meaning 100 years as its motif, is based on its proprietary antibody platform technology to treat cancer, autoimmune diseases, and brain nerve diseases. We are building pipelines in various fields, including therapeutics.

Santnaire’s core pipeline, the next-generation HER2-targeting antibody ‘CTN001’, is indicated for HER2-low-expressing breast cancer, not HER2-positive breast cancer, which is targeted by existing HER2-targeting antibodies. HER2 low-expression breast cancer is a newly classified cancer type that accounts for more than 50% of all breast cancers, but has great market potential as there is no approved target treatment.

Yang Ki-hyuk, CEO of Sanctnaire, said, "With this Series A investment, we will begin full-scale development and expansion of the antibody pipeline using platform technology," and added, "We will develop safe and effective antibody drugs, starting with our flagship pipeline ‘CTN001’. "We will prove Nair’s differentiated value," he said.

He continued, "CTN001 showed strong efficacy in HER2-low-expressing carcinomas that do not respond to the HER2-targeting antibody Herceptin in preclinical trials," adding, "Antibody-drug complex (ADC) and T-cell engage, which have recently shown positive results and are expanding treatment options for cancer patients. "As there are limits to its use as a combination treatment for early-stage cancer due to safety issues, CTN001 will be an alternative to overcome this," he emphasized.

Meanwhile, Sanctnair is a new bio company established by researchers, including CEO Yang Ki-hyuk, who was a founding member of Medytox and oversaw R&D, to develop a next-generation antibody platform based on innovative antibody technology introduced from Medytox. Sanctnaire is discussing collaboration in various fields with BioNote, which participated in the Series A investment, along with cooperation with its affiliate Medytox, and is pursuing the establishment of a network with several domestic universities and research institutes to improve the efficiency of research and development.

On March 23, 2022 AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, reported Thomas Equels, Chief Executive Officer of AIM, will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022 (Press release, AIM ImmunoTech, MAR 23, 2022, View Source [SID1234610675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the Company’s corporate presentation available on demand for registered attendees, Mr. Equels will participate in the "Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology" panel on Monday, March 28th at 12:00 PM ET.

During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITS, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/ Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

On March 23, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest (Press release, Cytori Therapeutics, MAR 23, 2022, View Source [SID1234610730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference will take place March 28-30, 2022, with pre-recorded presentations available on-demand through the conference portal at 2022 Virtual Growth Conference and available under the For Investors tab of the Plus website at www.plustherapeutics.com. This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member here: Reserve Your Seat.

On March 23, 2022 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported it is presenting new data in scientific posters at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, which will be held in-person and online, April 8-13, 2022 (Press release, Personalis, MAR 23, 2022, View Source [SID1234610757]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These abstracts demonstrate the full range of our capabilities in advancing the field of oncology, from a rich understanding of molecular-level interactions through clinical applications in multiple disease indications. The work also builds on the company’s strong foundation of genomic data generated with solid tumor tissue and expands into liquid biopsy with a unique, exome-wide approach," said Richard Chen, M.D., Chief Medical Officer and SVP of R&D of Personalis.

Personalis is presenting five posters, outlined below. Further details can be found at this link.

Title: Applying NeXT Liquid Biopsy, an exome-scale platform, to monitor and discover somatic variants in a broad set of cancer types
Overview: Circulating tumor cell-free DNA (ctDNA) has become a biomarker for prognosis and disease monitoring. However, studies typically utilize assays limited to a small set of genes that may miss biologically important and clinically actionable mutations. To address this limitation, we have developed a whole-exome scale cfDNA platform, NeXT Liquid Biopsy, that enables sensitive detection and tracking of somatic mutations in plasma samples across ~20,000 genes. The NeXT Liquid Biopsy platform monitors tumor variants and discovers novel mutations in the plasma, through analysis of tumor, normal and plasma samples from the same patient. The NeXT Liquid Biopsy platform enables the identification of somatic variants in liquid biopsy samples, following interventions such as surgery and treatment therapies. Here, we have applied NeXT Liquid Biopsy to profile the shedding of somatic mutations from more than 100 pan-cancer patients on an exome scale, detecting variants in well-characterized cancer driver genes and many events outside of traditional panel footprints.

Title: Accurate quantification of infiltrating B cell composition and clone diversity in tumor samples
Overview: The role of B cells as a prognostic biomarker remains elusive. For instance, infiltrating B cells in colorectal cancer have both positive and negative prognostic value. Thus, a scalable approach to quantify B cells and the B-cell receptor repertoire could yield novel insights into the role of B cells in tumor biology. To address this, we have developed immune cell quantification (InfiltrateIDTM) and immune receptor repertoire profiling (RepertoireIDTM) methods as part of the ImmunoID NeXT Platform, an augmented, immuno-oncology-optimized exome/transcriptome platform. We show that InfiltrateID and RepertoireID accurately capture the composition and clone diversity of infiltrating B cells in tumor samples. Furthermore, we apply the two methods to explore B cell infiltration and BCR repertoires across a set of more than 650 pan-cancer samples.

Title: Exome-scale longitudinal tracking of emerging therapeutic resistance in GIST via analysis of circulating tumor DNA
Overview: Gastrointestinal stromal tumors (GIST) are lethal tumors characterized by constitutively activating mutations to KIT or PDGFRA. Transient disease control in the first-line setting is achieved via inhibition of tyrosine kinase signaling using the KIT inhibitor imatinib. As patients progress through subsequent lines of therapy, a molecularly heterogeneous disease evolves, characterized by distinct subtypes and shifting repertoires of exon-specific KIT variants that directly impact treatment outcomes. This study uses tumor-informed exome-scale liquid biopsy to identify and track the evolution of multiple resistance mechanisms in patients receiving tyrosine kinase inhibitors (TKIs) to address the unmet need of comprehensive understanding of GIST evolution in response to therapy.

Title: A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimal residual disease at part per million resolution
Overview: Tumor-informed liquid biopsy approaches have proven promising for detecting minimal residual disease (MRD) and recurrence of cancer following surgical resection or other therapy. However, current liquid biopsy MRD assays typically detect ctDNA in a range above 30 to 300 parts per million (PPM), leaving a significant fraction of MRD cases undetected, particularly soon after surgery and in early-stage cancers where ctDNA can be at very low levels. To address this, Personalis has developed NeXT Personal, a tumor-informed liquid biopsy assay that achieves sensitivity down to 1 PPM, therefore enabling earlier detection of MRD and recurrence.

Title: Mono-allelic immunopeptidomics data from 109 MHC-I alleles reveals variability in binding preferences and improves neoantigen prediction algorithm
Overview: This study extends the previously published MHC-I, pan-allelic neoantigen prediction algorithm, SHERPA, with immunopeptidomics from 84 additional mono-allelic transfected cell lines, totaling data from 109 unique alleles. SHERPA achieves model generalizability and 98% population allelic coverage by integrating nearly 500 additional public immunopeptidomics samples. As a result, SHERPA identifies 1.38-fold more immunogenic epitopes than either NetMHCPan-4.1 and MHCFlurry-2.0 and reveals strong correlations between evolutionary divergence and influential binding pocket positions in the MHC allele.

On March 23, 2022 Ichnos Sciences Inc., a global biotechnology company developing novel multispecific antibodies for the treatment of cancer using the proprietary BEAT platform1, reported that preclinical data for ISB 1442, a first-in-class 2+1 biparatopic bispecific antibody that targets both CD38 and CD47, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in New Orleans from April 8-13, 2022 (Press release, Ichnos Sciences, MAR 23, 2022, View Source [SID1234610773]). ISB 1442 is being investigated as a treatment for relapsed/refractory multiple myeloma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data being presented at AACR (Free AACR Whitepaper) highlight the potential for ISB 1442, our first-in-class biparatopic CD38 x CD47 bispecific antibody, in multiple myeloma," said Stefano Sammicheli, Ph.D., Director of Innate Cell Engagers, at Ichnos Sciences. "This compound has shown higher potency and greater inhibition of tumor growth relative to daratumumab in both in vitro and in vivo models, suggesting that ISB 1442 may overcome common mechanisms of resistance to other CD38 targeted therapies, which is coupled with low potential for on-target off-tumor effects seen with other CD47 directed treatments."

"We are excited to have the opportunity to present at AACR (Free AACR Whitepaper), and to share ISB 1442 data that support our plan to move this drug into a Phase 1 study in the middle of this year," said Cyril Konto, M.D., President and Chief Executive Officer of Ichnos Sciences. "Advancing ISB 1442 is particularly important to Ichnos because it is built using BEAT 2.0, which is among the most advanced antibody engineering platforms and the basis of our discovery efforts for novel multispecifics to treat hematologic malignancies and solid tumors."

Ichnos Sciences continues to advance its pipeline of agents based on the proprietary BEAT technology platform. Using this platform, Ichnos Sciences is exploring the full design space for treating cancer and engineering multispecific antibodies capable of simultaneously engaging tumor and immune cells.

Details for the poster presentation are shared below:

Session PO.IM02.10 – Therapeutic Antibodies 2
April 12, 2022, 9:00 AM – 12:30 PM
2903 / 18 – ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies

Posters will be available on-demand on the AACR (Free AACR Whitepaper) website at www.aacr.org beginning at the start of the poster session and the abstract is available to view here.

1 Bispecific Engagement by Antibodies based on the TCR